Ascend Laboratories, 25 mg recall — Ascend Laboratories, LLC (Class II)

Ascend Laboratories, LLC is recorded by the U.S. Food and Drug Administration (FDA) as recalling Ascend Laboratories, 25 mg — a Class II recall, initiated 2026-04-27 and posted to the FDA enforcement report on 2026-05-20, under recall number D-0547-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Dissolution Specifications”. From the product description, the form is extended-release tablets, the strength given is 25 mg and it is marked Rx only. 1 National Drug Code number is printed in the record: 67877-590-01. Distribution is recorded as “U.S. Nationwide” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 98821. Ascend Laboratories, LLC accounts for 9 recall records in the indexed dataset. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0547-2026
FDA event ID 98821
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Ascend Laboratories, LLC
Recall initiated 2026-04-27
Reported by FDA 2026-05-20
Report lag 23 days from initiation to report
Distribution U.S. Nationwide — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-590-01.

Reason reported by FDA

Failed Dissolution Specifications

3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

6 identifying values matched by exact pattern in the 28-word product description above; each is a literal substring of it.

Product named Ascend Laboratories
Form Extended-Release Tablets
Strength 25 mg
NDC 67877-590-01
Marketing category Rx only
Manufactured by Alkem Laboratories Ltd., India
Distributed by Ascend Laboratories, LLC

Other indexed recalls from Ascend Laboratories, LLC

9 indexed records name Ascend Laboratories, LLC as the recalling firm, across 6 FDA events, reported 2026-05-20 to 2026-08-05. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Dabigatran Etexilate Capsules, 150 mgD-0737-2026Class III150 mg · Capsules2026-08-05
Dabigatran Etexilate Capsules, 75 mgD-0738-2026Class III75 mg · Capsules2026-08-05
Dabigatran Etexilate Capsules, 75 mgD-0739-2026Class III75 mg · Capsules2026-08-05
Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mgD-0712-2026Class II10 mg/20 mg · Tablets2026-07-29
Dabigatran etexilate Capsules, 110 mgD-0735-2026Class III110 mg · Capsules2026-07-29
Dabigatran etexilate Capsules, 150 mgD-0736-2026Class III150 mg · Capsules2026-07-29
Minocycline Hydrochloride Extended-Release Tablets, 115 mgD-0597-2026Class II115 mg · Extended-Release Tablets2026-06-17
Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mgD-0556-2026Class II5mg/40mg · Tablets2026-06-10

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Oasis Tears PF, 10mLD-0525-2026Oasis Medical, Inc.Class II2026-05-20
Buprenorphine Hydrochloride, 0.3mg/mLD-0527-2026Endo Usa, Inc.Class II2026-05-20
DELFLEX, 1.5%D-0512-2026Fresenius Medical Care Holdings, Inc.Class II2026-05-13
DELFLEX, 2.5%D-0513-2026Fresenius Medical Care Holdings, Inc.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 30 mgD-0514-2026Ajanta Pharma Ltd.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 60 mgD-0515-2026Ajanta Pharma Ltd.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 20 mgD-0516-2026Ajanta Pharma Ltd.Class II2026-05-13
BD PurPrep, 8.3%D-0517-2026Carefusion 213, LLCClass II2026-05-13

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 67877-590-01 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Ascend Laboratories, LLC (9 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0547-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0547-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-20
Ingested
2026-08-22
Record hash
5b21fb59a1992e8e

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.